Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

A summary of current health news details EU regulators probing Novo Nordisk's $16.5 billion Catalent takeover, Amgen's ...

is being developed to treat muscle atrophy that sometimes comes with weight loss drugs like Zepbound. Elsewhere, it is ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

The move puts Amazon in direct competition with Hims & Hers, a direct-to-consumer telehealth company that offers treatment ...